Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE R IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte R provides electrolytes and water to maintain or restore fluid balance, with bicarbonate precursors (acetate, gluconate) to buffer metabolic acidosis.
Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.
Fluid and electrolyte replacement for maintenance or restoration,Treatment of mild to moderate metabolic acidosis
Source of electrolytes, calories, and water for hydration in patients with or without carbohydrate deficiency,Maintenance and replacement of fluid and electrolyte losses in pediatric patients,Treatment of hypophosphatemia,Off-label: Total parenteral nutrition component
Intravenous infusion at a rate of 25-50 m L/kg body weight per 24 hours, adjusted for fluid and electrolyte needs. Typical adult maintenance dose: 1-2 L/day.
Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.
Not applicable (Plasma-Lyte R components are endogenous electrolytes and water; administered crystalloid redistributes rapidly; half-life of approximately 20-30 minutes for volume expansion due to renal excretion and redistribution into interstitial space)
Dextrose has a half-life of approximately 1.5–3 hours in patients with normal glucose metabolism; in renal failure, electrolyte half-lives may be prolonged. The half-life of sodium is about 2–4 hours, and potassium 2–6 hours, depending on renal function.
Not metabolized; acetate and gluconate are metabolized to bicarbonate in the liver and peripheral tissues.
Dextrose is metabolized via glycolysis to pyruvate then enters the TCA cycle. Acetate is metabolized via TCA cycle to bicarbonate. Phosphate is excreted renally or incorporated into ATP and other compounds.
Renal: >90% (electrolytes and water); Biliary/fecal: negligible (<5%)
Electrolytes are primarily excreted via renal pathways; dextrose is metabolized to CO2 and water, with negligible renal excretion. Specifically, sodium, potassium, magnesium, chloride, acetate, and gluconate are eliminated by the kidneys, with over 90% of infused electrolytes excreted renally.
Minimal (<5%); ions remain free in solution
Sodium, potassium, chloride, magnesium, and acetate have negligible protein binding (<5%); calcium is ~45% bound to albumin; gluconate binding is minimal.
Approximately 0.25-0.3 L/kg (limited to extracellular fluid compartment; distributes primarily in plasma and interstitial fluid)
Electrolytes distribute into total body water, approximately 0.6 L/kg for adults; dextrose distributes into extracellular fluid (~0.2 L/kg) but is rapidly taken up by cells.
Intravenous: 100%
Intravenous: 100% bioavailability.
Contraindicated in severe renal impairment (creatinine clearance < 30 m L/min) due to risk of hyperkalemia and fluid overload. For mild-to-moderate impairment (Cr Cl 30-89 m L/min), reduce infusion rate by 25-50% and monitor serum potassium.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia and fluid overload; for GFR 30-50 m L/min, use with caution and monitor potassium and fluid status.
Child-Pugh Class A: No adjustment. Child-Pugh B: Reduce infusion rate by 25% and monitor for fluid overload. Child-Pugh C: Avoid use due to risk of exacerbating ascites and electrolyte imbalances.
No specific dose adjustment for Child-Pugh class; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte imbalances.
Weight-based dosing: 20-100 m L/kg/day as a continuous infusion, with rate not exceeding 50 m L/kg/hour. Adjust based on hydration status, serum electrolytes, and renal function.
Intravenous infusion at a rate of 100-150 m L/kg/day for maintenance, adjusted based on weight, clinical condition, and electrolyte requirements.
Initiate at low end of dosing range (e.g., 25-30 m L/kg/day) due to age-related renal decline and increased risk of fluid overload. Monitor serum potassium, creatinine, and fluid balance closely.
Use with caution due to decreased renal function; start at lower infusion rates (e.g., 0.5-1 L per 24 hours) and monitor fluid and electrolyte status closely.
None.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to any component. Do not administer simultaneously with blood products through the same set due to risk of hemolysis.
Use with caution in patients with heart failure, renal impairment, or conditions with sodium retention,Monitor serum electrolytes and fluid balance,Risk of hypervolemia,Do not use if solution contains precipitate or if container is damaged
Risk of fluid overload, electrolyte disturbances, and hyperglycemia in patients with impaired renal function, cardiac failure, or diabetes,Use with caution in patients with severe hepatic disease (risk of lactic acidosis from acetate),Monitoring of serum electrolytes, glucose, fluid balance, and acid-base status is required,Avoid extravasation: risk of tissue necrosis
Hypernatremia,Hyperchloremia,Metabolic alkalosis,Severe renal impairment with oliguria,Hypersensitivity to any component
Hyperkalemia, hypernatremia, hyperphosphatemia, hypocalcemia,Severe metabolic alkalosis or lactic acidosis,Anuria or severe oliguria,Addison's disease (risk of hyperkalemia),Known hypersensitivity to any component
No known food interactions. However, patients on a sodium- or potassium-restricted diet should consult their physician before receiving this solution.
No specific food interactions. Patients should maintain a balanced diet as tolerated, but sodium and potassium intake may need monitoring or adjustment based on electrolyte status. Avoid excessive ingestion of high-sodium or high-potassium foods unless directed by clinician.
No evidence of teratogenicity. Plasma-Lyte R is an isotonic crystalloid solution; components (sodium, potassium, magnesium, chloride, acetate, gluconate) are physiological ions. No fetal risk identified in any trimester when used as indicated.
Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential ions and do not pose fetal risk when administered appropriately. Hyperglycemia from excessive dextrose may be associated with fetal macrosomia, neonatal hypoglycemia, and other metabolic disturbances, particularly in diabetic pregnancies. No specific trimester risks are identified for isotonic balanced solutions.
Compatible with breastfeeding. The components are normal blood constituents; no excretion into milk expected. M/P ratio not applicable; no risk to nursing infant.
Dextrose and electrolytes are normal constituents of breast milk. Infusion of ISOLYTE H with 5% dextrose does not alter milk composition or supply significantly. No adverse effects on breastfed infants are anticipated. The M/P ratio is not applicable as these are endogenous substances; no accumulation expected.
No dose adjustment required. Pregnancy does not alter pharmacokinetics of crystalloid solutions; administer based on clinical need for fluid and electrolyte replacement.
No specific dose adjustments for pregnancy; however, avoid excessive dextrose administration to prevent maternal hyperglycemia and fetal metabolic complications. Use with caution in gestational diabetes or preeclampsia; consider lower dextrose concentrations or rate adjustments based on maternal blood glucose and electrolyte levels.
Plasma-Lyte R is an isotonic crystalloid solution used for fluid and electrolyte resuscitation. It contains acetate and gluconate as buffers, which may be preferable in patients with lactic acidosis or hepatic dysfunction. Rapid infusion can cause volume overload; monitor renal function and serum electrolytes. Not recommended for patients with preexisting hyperkalemia.
ISOLYTE H with Dextrose 5% is a hypertonic solution (approx. 480 m Osm/L) used for fluid and electrolyte replacement in patients with hypochloremic metabolic alkalosis and fluid losses. It should be administered through a central line due to its high osmolarity. Monitor serum electrolytes, glucose, and acid-base status. Do not administer if solution is discolored or contains particulate matter.
Inform your healthcare provider if you have kidney problems, heart failure, or are on a sodium-restricted diet.,Report any signs of fluid overload, such as shortness of breath, swelling in the ankles or feet, or sudden weight gain.,This solution contains potassium; avoid potassium supplements or salt substitutes unless directed by your doctor.
This IV solution provides fluids, electrolytes, and calories to help correct imbalances caused by illness or surgery.,Tell your healthcare provider if you have a history of heart failure, kidney disease, or diabetes, as this solution may affect these conditions.,You may experience discomfort at the IV site; report any pain, redness, or swelling immediately.,Regular blood tests will be needed to monitor your electrolyte levels and kidney function.,Do not stop or adjust the infusion rate on your own.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE R IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE R IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte R provides electrolytes and water to maintain or restore fluid balance, with bicarbonate precursors (acetate, gluconate) to buffer metabolic acidosis.. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE R IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE R IN PLASTIC CONTAINER is: Intravenous infusion at a rate of 25-50 m L/kg body weight per 24 hours, adjusted for fluid and electrolyte needs. Typical adult maintenance dose: 1-2 L/day.. The standard adult dose of ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE R IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE R IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity. Plasma-Lyte R is an isotonic crystalloid solution; components (sodium, potassium, magnesium, chloride, acetate, gluconate) are physiological ions. No. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.